Ultragenyx trims headcount by 20%, cans Wilson disease gene therapy - FirstWord Pharma
FirstWord Pharma · Nov 4, 7:37 PM
Ultragenyx cuts staff after another study fails - STAT
STAT · Nov 4, 3:41 PM
Ultragenyx Pushes Toward Profitability in 2027, Led by Pruned Pipeline, Layoffs - Benzinga
Benzinga · Nov 4, 1:58 PM
Ultragenyx is a commercial-stage rare-disease company that sells Crysvita, Dojolvi, Mepsevii and Evkeeza and won FDA approval in 2026 for two gene therapies, GENGLYCOS (glycogen storage disease type Ia) and FAYUVI (Sanfilippo syndrome type A).
Ultragenyx depends on marketed rare-disease revenue, GENGLYCOS and FAYUVI launches, and substantial spending cuts to deliver management's 2027 profitability target. UX701's termination and GTX-102's wind-down further narrow pipeline growth. Cash and securities were $401 million at September 30, 2026, before the GENGLYCOS voucher sale closed; the FAYUVI sale remains pending. Combined net voucher proceeds are expected to be approximately $350 million. Revenue guidance excludes new launches. DTX301's second primary endpoint remains expected in the first half of 2027.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: Revenue and the voucher sale reach profitability in 2027
Do completed voucher sales, commercial growth and realized expense cuts support management's recurring profitability target?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Pipeline exits increase reliance on gene therapy launches and spending cuts
FAYUVI becomes Ultragenyx’s second approved gene therapy; Aspire failure still weighs on growth
GTX-102 misses Phase 3 Aspire endpoints, removing a growth driver and forcing a program review
GENGLYCOS (DTX401) receives FDA accelerated approval for GSDIa
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neuromuscular diseases, Neurology and pain, Obesity, diabetes and heart disease, Endocrine and bone diseases, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
6 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.